Overexpression of factor inhibiting HIF-1 enhances vessel maturation and tumor growth via platelet-derived growth factor-C

International Journal of Cancer

Volumn 131, Issue 5, 2012, Pages

  Kuzmanov, Aleksandar ^a   Wielockx, Ben ^a   Rezaei, Maryam ^a   Kettelhake, Antje ^a   Breier, Georg ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Factor inhibiting HIF; PDGF receptor a; Platelet derived growth factor C; Tumor progression; Vessel maturation

Indexed keywords

FACTOR INHIBITING HYPOXIA INDUCIBLE FACTOR 1; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FACTOR INHIBITING HYPOXIA INDUCIBLE FACTOR 1 GENE; FEMALE; GAIN OF FUNCTION MUTATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; INTRACELLULAR SIGNALING; LOSS OF FUNCTION MUTATION; MOUSE; NONHUMAN; ONCOGENE; OSTEOSARCOMA; PERICYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH; TUMOR VASCULARIZATION; UPREGULATION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL PROLIFERATION; FEMALE; HYPOXIA-INDUCIBLE FACTOR 1; IMMUNOENZYME TECHNIQUES; LYMPHOKINES; MICE; MICE, INBRED C3H; MIXED FUNCTION OXYGENASES; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; PERICYTES; PLATELET-DERIVED GROWTH FACTOR; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84863190947     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27360     Document Type: Article

References (49)

1. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors. Cancer Res 1989;49:6449-65. (Pubitemid 20008770)
2. Ryan HE, Poloni M, McNulty W, Elson D, Gassman M, Arbeit JM, Johnson RS. Hypoxiainducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 2000;60:4010-15. (Pubitemid 30636574)
3. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6. (Pubitemid 20020880)
4. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-80. (Pubitemid 30660013)
5. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003;163:1801-15. (Pubitemid 37310012)
6. 2 availability on human cancer. Nat Rev Cancer 2008;8:967-75.
7. Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 2009;19:12-16.
8. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, Semenza GL. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61:2911-16. (Pubitemid 32691934)
9. Zhong H, DeMarzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1 in common human cancers and their metastases. Cancer Res 1999;59:5830-35.
10. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998;17:3005-15. (Pubitemid 28254373)
11. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, Ferrara N, Johnson RS. Loss of HIF-1alpha in endothelial cells disrupts a hypoxiadriven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004;6:485-95. (Pubitemid 39469984)
12. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-72. (Pubitemid 32335942)
13. Kaelin WG. Proline hydroxylation and gene expression. Annu Rev Biochem 2005;74:115-28.
14. Erez N, Milyavsky M, Eilam R, Shats I, Goldfinger N, Rotter V. Expression of prolylhydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Cancer Res 2003;63:8777-83. (Pubitemid 38064057)
15. Chan DA, Kawahara TLA, Sutphin PD, Chang HY, Chi JT, Giaccia AJ. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 2009;15:527-38.
16. Ameln KA, Muschter A, Mamlouk S, Kalucka J, Prade I, Franke K, Rezaei M, Poitz DM, Breier G, Wielockx B. Inhibition of HIF Prolyl Hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGFb. Cancer Res 2011;71:3306-16.
17. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004;5:343-54. (Pubitemid 38579472)
18. Dayan F, Roux D, Brahimi-Horn MC, Pouyssegur J, Mazure NM. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res 2006;66:3688-98.
19. Koivunen P, HirsilaM, Gunzler V, Kivirikko KI, Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 2004;279:9899-04.
20. Zhang Na, Fu Z, Linke S, Chicher J, Gorman JJ, Visk D, Haddad GG, Poellinger L, Peet DJ, Powell F, Johnson RS. The asparaginyl hydroxylase factor inhibiting HIF-1a is an essential regulator of metabolism. Cell Metabolism 2010;11:364-78.
21. Soilleux EJ, Turley H, Tian YM, Pugh CW, Gatter KC, Harris AL. Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues. Histopathol 2005;47:602-10. (Pubitemid 41775183)
22. Dagnon K, Pacary E, Commo F, Antoine M, Bernaudin M, Bernaudin J, Callard P. Expression of Erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res 2005;11:993-99. (Pubitemid 40175746)
23. Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC, Harris AL, Fox SB. Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer. Breast Cancer Res 2007;9:1-10.
24. Stolze IP, Tian YM, Appelhoff RJ, Turley H, Wykoff CC, Gleadle JM, Ratcliffe PJ. Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional target genes. J Biol Chem 2004;279:42719-25. (Pubitemid 39372158)
25. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001;15:2675-86. (Pubitemid 32988878)
26. Cockman ME, Lancaster DE, Stolze IP, Hewitson KS, McDonough MA, Coleman ML, Coles CH, Yu X, Hay RT, Ley SC, Pugh CW, Oldham NJ, et al. Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxiainducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc Natl Acad Sci USA 2006;103:14767-72. (Pubitemid 44527803)
27. Coleman ML, McDonough MA, Hewitson KS, Coles C, Mecinovic J, Edelmann M, Cook KM, Cockman ME, Lancaster DE, Kessler BM, Oldham NJ, Ratcliffe PJ, et al. Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor inhibiting hypoxiainducible factor. J Biol Chem 2007;282:24027-38. (Pubitemid 47328043)
28. Ferguson JE, Wu Y, Smith K, Charles P, Powers K, Wang H, Patterson C. ASB4 is a hydroxylation substrate of FIH and promotes vascular differentiation via an oxygendependent mechanism. Mol Cell Biol 2007;27:6407-19. (Pubitemid 47435747)
29. Labelle M, Schnittler HJ, Aust DE, Friedrich K, Baretton G, Vestweber D, Breier G. Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor B signalling. Cancer Res 2008;68:1388-97. (Pubitemid 351346846)
30. Vecchi A, Garlanda C, Lampugnani MG, Resnati M, Matteucci C, Stoppacciaro A, Schnurch H, Risau W, Ruco L, Mantovani A, Dejana E. Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur J Cell Biol 1994;63:247-54. (Pubitemid 24132219)
31. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, Tian Y, Lanahan AA, Pollard P, Ruiz de Almodovar C, De Smet F, Vinckier S, Aragone J, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009;136:1-13.
32. Furuhashi M, Sjöblom T, Abramsson A, Ellingsen J, Micke P, Li H, Bergsten-Folestad E, Eriksson U, Heuchel R, Betsholtz C, Heldin C, Ostman A. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res 2004;64:2725-33. (Pubitemid 38500608)
33. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. (Pubitemid 40093472)
34. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160:985-1000. (Pubitemid 34224587)
35. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003;314:15-23. (Pubitemid 37409909)
36. Nehls V, Drenckhahn D. Heterogeneity of microvascular pericytes for smooth muscle type a-actin. J Cell Biol 1991;113:147-54. (Pubitemid 21909681)
37. Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, Deppermann C, Schadendorf D, Thurston G, Fiedler U, Augustin HG. Hostderived Angiopoietin-2 affects early stages of tumor development and vessel maturation, but is dispensable for later stages of tumor growth. Cancer Res 2009;69:1324-33.
38. Hawighorst T, Skobe M, Streit M, Hong YK, Velasco P, Brown LF, Riccardi L, Lange-Asschenfeldt B, Detmar M. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 2002;160:1381-92. (Pubitemid 34411642)
39. Machein MR, Knedla A, Knoth R, Wagner S, Neuschl E, Plate KH. Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. Am J Pathol 2004;165:1557-70. (Pubitemid 39435155)
40. Li H, Fredriksson L, Li X, Eriksson U. PDGF-D is a potent transforming and angiogenic growth factor. Oncogene 2003;22:1501-10. (Pubitemid 36390599)
41. Tomaso E, London N, Fuja D, Logie J, Tyrrell JA, Kamoun W, Munn LL, Jain RK. PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS ONE 2009;4:1-8.
42. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003,9:685-93. (Pubitemid 36749217)
43. Duffy JP, Eibl G, Reber HA, Hines O. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer 2003;2:1-10.
44. Vaupel P. The role of hypoxia-induced factors in tumor progression. The Oncologist 2004;9:10-17. (Pubitemid 39658341)
45. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-48.
46. Breier G, Blum S, Peli J, Groot M, Wild C, Risau W, Reichmann E. Transforming growth factor-b1 and Ras regulate the VEGF/VEGF receptor system during tumor angiogenesis. Int J Cancer 2002;97:142-48. (Pubitemid 34019947)
47. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485-90. (Pubitemid 28373960)
48. Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L, Fukumura D, Moreno-Murciano MP, Herbert JM, Burger A, Riedel J, Elvert G, et al. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell 2005;8:131-41. (Pubitemid 41132742)
49. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G. Blockade of Dll4 inhibits tumour growth by promoting nonproductive angiogenesis. Nature 2006;444:1032-37. (Pubitemid 46018516)